Dr. Kevin M. Fox '05 has been selected for the inaugural 2013 Du-Co Ceramics Y...
Mark Kester
G. Thomas Passananti Professor of Pharmacology
Director, Penn State Center for NanoMedicine and Materials
Co-Leader, Experimental Therapeutics, Penn State Hershey Cancer Institute
Penn State University College of Medicine
500 University Drive
Hershey, PA 17110
717 531 8964
mkester@psu.edu
1. Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, Staveley-O'Carroll KF. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology. 2012 Jan; 55(1):141-52.
2. Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M. Exogenous Ceramide-1-phosphate Reduces Lipopolysaccharide (LPS)-mediated Cytokine Expression. J Biol Chem. 2011 Dec 30; 286(52):44357-66.
3. Barth BM, Cabot MC, Kester M. Ceramide-based therapeutics for the treatment of cancer. Anticancer Agents Med Chem. 2011 Nov 1; 11(9):911-9.
4. Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastaticmelanoma. Ann Pharmacother. 2011 Nov; 45(11):1399-405.
Dr. Kevin M. Fox '05 has been selected for the inaugural 2013 Du-Co Ceramics Y...
Dr. Zi-Kui Liu, Professor of Ma...
David Saint John, a 2012 MatSC grad and instructor in Penn State's College of...
Donald W. Hamer, a 1968 Penn State alumnus and 2013 recipient of the Materials Sci...
Neal Lewis, a junior performing undergraduate research in Professor Clive Randall...
The 40th Taylor Lecture was given on April 23, 2013, by P.M. Ajayan, the Benjamin...
Beecher Watson III, undergraduate student advised by Dr. Douglas Wolfe won the...
Dr. Michael Hickner receive...